A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
Cervical Cancer|Gastric Cancer|Stomach Cancer|Gastroesophageal Junction Cancer|Esophageal Cancer|Hepatocellular Carcinoma|Melanoma|Uveal Melanoma|Merkel Cell Carcinoma|Mesothelioma|MSI|Non-small Cell Lung Cancer|NSCLC|Ovarian Cancer|Squamous Cell Carcinoma of the Head and Neck|Small Cell Lung Cancer|Renal Cell Carcinoma|RCC|Triple-negative Breast Cancer|Urothelial Carcinoma|Mismatch Repair Deficiency
DRUG: INCAGN02390
Number of treatment-emergent adverse events, Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug., Up to 12 months|Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only), PAD defined as a dose that achieves a level of receptor occupancy considered to be biologically active., Up to approximately 1 month
Cmax of INCAGN02390, Maximum observed plasma or serum concentration., Up to 12 months|Tmax of INCAGN02390, Time to maximum concentration., Up to 12 months|Cmin of INCAGN02390, Minimum observed plasma or serum concentration over the dose interval., Up to 12 months|AUC0-t of INCAGN02390, Area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t., Up to 12 months|Objective response rate, Defined as the percentage of participants having complete response (CR) or partial response (PR) determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1., Up to 12 months|Duration of response, Defined as time from earliest date of disease response (CR or PR) until earliest date of disease progression (determined by investigator assessment of radiographic disease per RECIST v1.1) or death from any cause, if occurring sooner than progression., Up to 12 months|Disease control rate, Defined as percentage of participants having CR, PR, or stable disease as best on-study response., Up to 12 months|Progression-free survival, Defined as the time from date of first dose of study drug until the earliest date of disease progression (determined by investigator assessment of objective radiographic disease per RECIST v1.1) or death from any cause if occurring sooner than progression., Up to 12 months|Level of binding of INCAGN02390 to TIM-3, Assessed from participant whole blood samples., Up to approximately 3 months|Immunogenicity of INCAGN02390, Defined as the occurrence of specific ADA to INCAGN02390., Up to 12 months
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.